Nose as a route for drug delivery

Nasal Physiology and Pathophysiology of Nasal Disorders

Volumn , Issue , 2013, Pages 191-215

  Serralheiro, Ana ^a,b   Alves, Gilberto ^c   Sousa, Joana ^a,b   Fortuna, Ana ^a,b   Falcão, Amílcar ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF BEIRA INTERIOR   (Portugal)

Author keywords

Biomolecular drugs; Central nervous system acting drugs; Intranasal administration; Intranasal delivery; Nasal drug delivery; Nasal route; Nasal therapeutic agents; Small molecule drugs; Systemic drugs; Topical drugs

Indexed keywords

EID: 84925941475     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-37250-6_15     Document Type: Chapter

References (174)

1. Adappa ND, Wei CC, Palmer J. Nasal irrigation with or without drugs: The evidence. Curr Opin Otolaryngol Head Neck Surg. 2012;20:23-57.
2. Ahmed S, Sileno AP, deMeireles JC, et al. Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects. Pharm Res. 2000;17:974-7.
3. Ahn B-N, Kim S-K, Shim C-K. Proliposomes as an intranasal dosage form for the sustained delivery of propranolol. J Contol Release. 1995; 34:203-10.
4. Akpinar ME, Yigit O, Akakin D, et al. Topical glucocorticoid reduces the topical decongestant-induced histologic changes in an animal model nasal mucosa. Laryngoscope. 2012;122:741-6.
5. Alsarra IA, Hamed AY, Alanazi FK. Acyclovir liposomes for intranasal systemic delivery: development and pharmacokinetics evaluation. Drug Deliv. 2008;15:313-21.
6. Alsarra IA, Hamed AY, Alanazi FK, et al. Vesicular systems for intranasal drug delivery. In: Jain KK, editor. Drug delivery to the central nervous system. New York: Humana; 2010. doi: 10.1007/978-1-60761-529-3-8.
7. Anderson BD. Prodrugs for improved CNS delivery. Adv Drug Deliv Rev. 1996;19:171-202.
8. Anderson JM, Etches D. Prevention and management of postpartum hemorrhage. Am Fam Physician. 2007;75: 875-82.
9. Arnott N, Harrold AJ, Lynch P. Variations in oxytocin regimes in Scottish labour wards in 1998. J Obstet Gynaecol. 2000;20:235-8.
10. Arora P, Sharma S, Garg S. Permeability issues in nasal drug delivery. Drug Discov Today. 2002;7:967-75.
11. Atluri H, Tirucherai GS, Dias CS, et al. Ocular, nasal, pulmonary and otic routes of drug delivery. In: Jasti BR, Ghosh TK, editors. Theory and practice of contemporary pharmaceutics. New York: CRC Press; 2005. doi: 10.1201/9780203644478.ch16.
12. Babey M, Kopp P, Robertson GL. Familial forms of diabetes insipidus: clinical and molecular characteristics. Nat Rev Endocrinol. 2011;7:701-14.
13. Bahadur S, Pathak K. Physicochemical and physiological considerations for efficient nose-to-brain targeting. Expert Opin Drug Deliv. 2012;9:19-31.
14. Balasubramanian R, Dwyer A, Seminara SB, et al. Human GnRH deficiency: A unique disease model to unravel the ontogeny of GnRH neurons. Neuroendocrinology. 2010;92:81-99.
15. Barakat NS, Omar SA, Ahmed AA. Carbamazepine uptake into rat brain following intra-olfactory transport. J Pharm Pharmacol. 2006;58:63-72.
16. Behl CR, Pimplaskar HK, Sileno AP, et al. Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv Drug Deliv Rev. 1998;29:89-116.
17. Bellad M, Tara D, Ganachari M, et al. Prevention of postpartum haemorrhage with sublingual misoprostol or oxytocin: A double-blind randomised controlled trial. BJOG. 2012;119:975-86.
18. Bende M, Löth S. Vascular effects of topical oxymetazoline on human nasal mucosa. J Laryngol Otol. 1986; 100:285-8.
19. Benedict C, Brede S, Schiöth HB, et al. Intranasal insulin enhances postprandial thermogenesis and lowers postprandial serum insulin levels in healthy men. Diabetes. 2011;60:114-8.
20. Berglund RK, Tangen CM, Powell IJ, et al. Ten-year follow- up of neoadjuvant therapy with goserelin acetate and fl utamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109. Urology. 2012;79:633-7.
21. Bitter C, Suter-Zimmermann K, Surber C. Nasal drug delivery in humans. Curr Probl Dermatol. 2011;40: 20-35.
22. Caenen M, Hamels K, Deron P, et al. Comparison of decongestive capacity of xylometazoline and pseudoephedrine with rhinomanometry and MRI. Rhinology. 2005;43:205-9.
23. Cass LM, Efthymiopoulos C, Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet. 1999;36:1-11.
24. Chadwick S, Kriegel C, Amiji M. Nanotechnology solutions for mucosal immunization. Adv Drug Deliv Rev. 2010;62:394-407.
25. Chanson P, Salenave S. Treatment of neurogenic diabetes insipidus. Ann Endocrinol (Paris). 2011;72:496-9.
26. Chen M, Li XR, Zhou YX, et al. Improved absorption of salmon calcitonin by ultraflexible liposomes through intranasal delivery. Peptides. 2009; 30:1288-95.
27. Chesnut 3rd CH, Azria M, Silverman S, et al. Salmon calcitonin: A review of current and future therapeutic indications. Osteoporos Int. 2008;19:479-91.
28. Cho E, Gwak H, Chun I. Formulation and evaluation of ondansetron nasal delivery systems. Int J Pharm. 2008;349:101-7.
29. Christrup LL, Foster D, Popper LD, et al. Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: A randomized, double-blind, double-dummy, two-way, crossover study. Clin Ther. 2008;30:469-81.
30. Colombo G, Lorenzini L, Zironi E, et al. Brain distribution of ribavirin after intranasal administration. Antiviral Res. 2011;92:408-14.
31. Corboz MR, Rivelli MA, Mingo GG, et al. Mechanism of decongestant activity of alpha 2-adrenoceptor agonists. Pulm Pharmacol Ther. 2008;21:449-54.
32. Costantino HR, Illum L, Brandt G, et al. Intranasal delivery: Physicochemical and therapeutic aspects. Int J Pharm. 2007;337:1-24.
33. Costantino HR, Leonard AK, Brandt G, et al. Intranasal administration of acetylcholinesterase inhibitors. BMC Neurosci. 2008;9 Suppl 3:S6.
34. Csaba N, Gracia-Fuentes M, Alonso MJ. Nanoparticles for nasal vaccination. Adv Drug Deliv Rev. 2009;61: 140-57.
35. Dahlin M, Björk E. Nasal administration of a physostigmine analogue (NXX-066) for Alzheimer's disease to rats. Int J Pharm. 2001;212:267-74.
36. Dahlin M, Bergman U, Jansson B, et al. Transfer of dopamine in the olfactory pathway following nasal administration in mice. Pharm Res. 2000;17:737-42.
37. Dahlin M, Jansson B, Björk E. Levels of dopamine in blood and brain following nasal administration to rats. Eur J Pharm Sci. 2001;14:75-80.
38. Deveci S, Peskircioglu L, Aygün C, et al. Sublingual sildenafil in the treatment of erectile dysfunction: Faster onset of action with less dose. Int J Urol. 2004; 11:989-92.
39. Devogelaer JP, Boutsen Y, Manicourt DH. Biologicals in osteoporosis: Teriparatide and parathyroid hormone in women and men. Curr Osteoporos Rep. 2010;8: 154-61.
40. Dhuria SV, Hanson LR, Frey 2nd WH. Intranasal delivery to the central nervous system: Mechanisms and experimental considerations. J Pharm Sci. 2010;99: 1654-73.
41. Dodick D, Brandes J, Elkind A, et al. Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: A randomised, double- blind, placebo-controlled study. CNS Drugs. 2005;19:125-36.
42. du Plessis LH, Lubbe J, Strauss T, et al. Enhancement of nasal and intestinal calcitonin delivery by the novel Pheroid TM fatty acid based delivery system, and by N -trimethyl chitosan chloride. Int J Pharm. 2010;385: 181-6.
43. Dykewicz MS, Hamilos DL. Rhinitis and sinusitis. J Allergy Clin Immunol. 2010;125 Suppl 2:S103-15.
44. Elshafeey AH, Bendas ER, Mohamed OH. Intranasal micro emulsion of sildenafil citrate: In vitro evaluation and in vivo pharmacokinetic study in rabbits. AAPS PharmSciTech. 2009;10:361-7.
45. EMA, European Medicines Agency. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001101/human-med-001405.jsp&mid=WC0b01ac058001d124 (2012). Accessed 13 July 2012.
46. Falser N, Wober W, Rahlfs VW, et al. Comparative efficacy and safety of azelastine and levocabastine nasal sprays in patients with seasonal allergic rhinitis. Arzneimittelforschung. 2001;51:387-93.
47. FDAa - U.S. Food and Drug Administration. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm (2012). Accessed 13 July 2012.
48. FDAb - U.S. Food and Drug Administration. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm (2012). Accessed 13 July 2012.
49. Fewtrell MS, Loh KL, Blake A, et al. Randomised, double blind trial of oxytocin nasal spray in mothers expressing breast milk for preterm infants. Arch Dis Child Fetal Neonatal Ed. 2006;91:F169-74.
50. Fisher A, Watling M, Smith A, et al. Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. Int J Clin Pharmacol Ther. 2010;48:138-45.
51. Fitzgibbon D, Morgan D, Dockter D, et al. Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients. Pain. 2003;106:309-15.
52. Florence K, Manisha L, Kumar BA, et al. Intranasal clobazam delivery in the treatment of status epilepticus. J Pharm Sci. 2011;100:692-703.
53. Foreman A, Boase S, Psaltis A, et al. Role of bacterial and fungal biofilms in chronic rhinosinusitis. Curr Allergy Asthma Rep. 2012;12:127-35.
54. Franco Jr JG, Baruffi RL, Mauri AL, et al. Prospective randomized comparison of ovarian blockade with nafarelin versus leuprolide during ovarian stimulation with recombinant FSH in an ICSI program. J Assist Reprod Genet. 2001;18:593-7.
55. Fransén N, Bredenberg S, Björk E. Clinical study shows improved absorption of desmopressin with novel formulation. Pharm Res. 2009;26:1618-25.
56. Gao L, Yu S, Chen Q, et al. A randomized controlled trial of low-dose recombinant human interferons alpha-2b nasal spray to prevent acute viral respiratory infections in military recruits. Vaccine. 2010;28:4445-51.
57. Gawel M, Aschoff J, May A, et al. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine-results from phase 1 of the REALIZE Study. Headache. 2005;45:7-16.
58. Giavina-Bianchi P, Agondi R, Stelmach R, et al. Fluticasone furoate nasal spray in the treatment of allergic rhinitis. Ther Clin Risk Manag. 2008;4:465-72.
59. Goodsell A, Zhou F, Gupta S, et al. Beta7-integrinindependent enhancement of mucosal and systemic anti-HIV antibody responses following combined mucosal and systemic gene delivery. Immunology. 2008;123:378-89.
60. Graf P. Rhinitis medicamentosa: Aspects of pathophysiology and treatment. Allergy. 1997;52 Suppl 4:28-34.
61. Grassin-Delyle S, Buenestado A, Naline E, et al. Intranasal drug delivery: An efficient and non-invasive route for systemic administration: Focus on opioids. Pharmacol Ther. 2012;134:366-79.
62. Gungor S, Okyar A, Erturk-Toker S, et al. Ondansetronloaded chitosan microspheres for nasal antiemetic drug delivery: An alternative approach to oral and parenteral routes. Drug Dev Ind Pharm. 2010;36:806-13.
63. Gupta H, Sharma A. Recent trends in protein and peptide drug delivery systems. Asian J Pharm. 2009;3:69-75. Available from: http://www.asiapharmaceutics.info/text.asp?2009/3/2/69/55041. Accessed 13 July 2012.
64. Hallschmid M, Higgs S, Thienel M, et al. Postprandial administration of intranasal insulin intensifies satiety and reduces intake of palatable snacks in women. Diabetes. 2012;61:782-9.
65. Hanson LR, Frey 2nd WH. Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS. J Neuroimmune Pharmacol. 2007; 2:81-6.
66. Hanson LR, Frey 2nd WH. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 2008;9 Suppl 3:S5.
67. Hinkula J, Hagbom M, Wahren B, et al. Safety and immunogenicity, after nasal application of HIV-1 DNA gagp37 plasmid vaccine in young mice. Vaccine. 2008;26:5101-6.
68. Hochban W, Althoff H, Ziegler A. Nasal decongestion with imidazoline derivatives: Acoustic rhinometry measurements. Eur J Clin Pharmacol. 1999;55:7-12.
69. Howarth PH. A comparison of the anti-inflammatory properties of intranasal corticosteroids and antihistamines in allergic rhinitis. Allergy. 2000;62:6-11.
70. Hussain AA, Dakkuri A, Itoh S. Nasal absorption of ondansetron in rats: An alternative route of drug delivery. Cancer Chemother Pharmacol. 2000;45:432-4.
71. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci. 2000;11: 1-18.
72. Illum L. Nasal drug delivery: new developments and strategies. Drug Discov Today. 2002;7:1184-9.
73. Illum L. Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol. 2004;56:3-17.
74. Illum L. Nasal drug delivery - recent developments and future prospects. J Control Release. 2012; 161:254-63.
75. Illum L, Watts P, Fisher AN, et al. Intranasal delivery of morphine. J Pharmacol Exp Ther. 2002;301: 391-400.
76. Jain R, Nabar S, Dandekar P, et al. Micellar nanocarriers: Potential nose-to-brain delivery of zolmitriptan as novel migraine therapy. Pharm Res. 2010;27:655-64.
77. Jiang L, Gao L, Wang X, et al. The application of mucoadhesive polymers in nasal drug delivery. Drug Dev Ind Pharm. 2010;36:323-36.
78. Jogani VV, Shah PJ, Mishra P, et al. Nose-to-brain delivery of tacrine. J Pharm Pharmacol. 2007;59:1199-205.
79. Jogani V, Jinturkar K, Vyas T, et al. Recent patents review on intranasal administration for CNS drug delivery. Recent Pat Drug Deliv Formul. 2008;2:25-40.
80. Kaasa S, Moksnes K, Nolte T, et al. Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. J Opioid Manag. 2010; 6:17-26.
81. Kaliner MA, Storms W, Tilles S, et al. Comparison of olopatadine 0.6% nasal spray versus fl uticasone propionate 50 microg in the treatment of seasonal allergic rhinitis. Allergy Asthma Proc. 2009;30:255-62.
82. Kang ML, Cho CS, Yoo HS. Application of chitosan microspheres for nasal delivery of vaccines. Biotechnol Adv. 2009;27:857-65.
83. Kao HD, Traboulsi A, Itoh S, et al. Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs. Pharm Res. 2000;17:978-84.
84. Kim TK, Kang W, Chun IK, et al. Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems. Eur J Pharm Sci. 2009; 38:525-32.
85. Köping-Höggård M, Sánchez A, Alonso MJ. Nanoparticles as carriers for nasal vaccine delivery. Expert Rev Vaccines. 2005;4:185-96.
86. Kubota R, Komiyama T, Shimada H. Evaluation of the method for nifedipine administration for a rapid onset of clinical effect: A clinical study in normal volunteers. Yakugaku Zasshi. 2001;121:355-64.
87. Kumar M, Misra A, Babbar AK, et al. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm. 2008;358:285-91.
88. Lee HJ, Macbeth AH, Pagani JH, et al. Oxytocin: The great facilitator of life. Prog Neurobiol. 2009;88: 127-51.
89. Lee SL, Yu LX, Cai B, et al. Scientific considerations for generic synthetic salmon calcitonin nasal spray products. AAPS J. 2011;13:14-9.
90. Lerner EN, van Zanten EH, Stewart GR. Enhanced delivery of octreotide to the brain via transnasal iontophoretic administration. J Drug Target. 2004;12:273-80.
91. Li L, Gorukanti S, Choi YM, et al. Rapid-onset intranasal delivery of anticonvulsants: Pharmacokinetic and pharmacodynamic evaluation in rabbits. Int J Pharm. 2000;199:65-76.
92. Li L, Nandi I, Kim KH. Development of an ethyl lauratebased microemulsion for rapid-onset intranasal delivery of diazepam. Int J Pharm. 2002;237:77-85.
93. Li R, Lim A, Alonso S. Attenuated Bordetella pertussis BPZE1 as a live vehicle for heterologous vaccine antigens delivery through the nasal route. Bioeng Bugs. 2011;2:315-9.
94. Lim M, Citardi MJ, Leong JL. Topical antimicrobials in the management of chronic rhinosinusitis: A systematic review. Am J Rhinol. 2008;22:381-9.
95. Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2012;64:614-28.
96. Lorenzi JC, Trombone AP, Rocha CD, et al. Intranasal vaccination with messenger RNA as a new approach in gene therapy: use against tuberculosis. BMC Biotechnol. 2010;10:77.
97. Mahajan HS, Gattani S. In situ gels of metoclopramide hydrochloride for intranasal delivery: In vitro evaluation and in vivo pharmacokinetic study in rabbits. Drug Deliv. 2010;17:19-27.
98. Maranta CA, Simmen D. Decongestant nasal spray. Results of a rhinomanometric double-blind study. Schweiz Med Wochenschr. 1996;126:1875-80.
99. Mathias NR, Hussain MA. Non-invasive systemic drug delivery: developability considerations for alternate routes of administration. J Pharm Sci. 2010;99:1-20.
100. Medina M, Vintiñi E, Villena J. Lactococcus lactis as an adjuvant and delivery vehicle of antigens against pneumococcal respiratory infections. Bioeng Bugs. 2010;1:313-25.
101. Meltzer EO, Caballero F, Fromer LM, et al. Treatment of congestion in upper respiratory diseases. Int J Gen Med. 2010;3:69-91.
102. Merkus FW, Van den Berg MP. Can nasal drug delivery bypass the blood-brain barrier? Questioning the direct transport theory. Drugs R D. 2007;8:133-44.
103. Misra A, Ganesh S, Shahiwala A, et al. Drug delivery to the central nervous system: A review. J Pharm Pharm Sci. 2003;6:252-73.
104. Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm. 2009;379: 146-57.
105. Moenter SM. Identified GnRH neuron electrophysiology: A decade of study. Brain Res. 2010;1364:10-24.
106. Nevéus T. Nocturnal enuresis - Theoretic background and practical guidelines. Pediatr Nephrol. 2011; 26:1207-14.
107. Ozgönenel B, Rajpurkar M, Lusher JM. How do you treat bleeding disorders with desmopressin? Postgrad Med J. 2007;83:159-63.
108. Ozsoy Y, Gungor S, Cevher E. Nasal delivery of high molecular weight drugs. Molecules. 2009; 14:3754-79.
109. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106:2194-9.
110. Parra AL, Rodriguez JC. Nasal neuro EPO could be a reliable choice for neuroprotective stroke treatment. Cent Nerv Syst Agents Med Chem. 2012;12:60-8.
111. Patil S, Babbar A, Mathur R, et al. Mucoadhesive chitosan microspheres of carvedilol for nasal administration. J Drug Target. 2010;18:321-31.
112. Patil SB, Kaul A, Babbar A, et al. In vivo evaluation of alginate microspheres of carvedilol for nasal delivery. J Biomed Mater Res B Appl Biomater. 2012;100: 249-55.
113. Petersen H, Kullberg A, Edsbäcker S, et al. Nasal retention of budesonide and fluticasone in man: Formation of airway mucosal budesonide-esters in vivo. Br J Clin Pharmacol. 2001;51:159-63.
114. Pires A, Fortuna A, Alves G, et al. Intranasal drug delivery: how, why and what for? J Pharm Pharm Sci. 2009;12:288-311.
115. Rajinikanth PS, Sankar C, Mishra B. Sodium alginate microspheres of metoprolol tartrate for intranasal systemic delivery: development and evaluation. Drug Deliv. 2003;10:21-8.
116. Rautio J, Laine K, Gynther M, et al. Prodrug approaches for CNS delivery. AAPS J. 2008;10:92-102.
117. Roland PS, Marple BF, Wall GM. Olopatadine nasal spray for the treatment of allergic rhinitis. Expert Rev Clin Immunol. 2010;6:197-204.
118. Ross TM, Martinez PM, Renner JC, et al. Intranasal administration of interferon beta bypasses the blood- brain barrier to target the central nervous system and cervical lymph nodes: A non-invasive treatment strategy for multiple sclerosis. J Neuroimmunol. 2004;151: 66-77.
119. Ruis H, Rolland R, Doesburg W, et al. Oxytocin enhances onset of lactation among mothers delivering prematurely. Br Med J (Clin Res Ed). 1981;283:340-2.
120. Safdarian L, Mohammadi FS, Alleyassin A, et al. Clinical outcome with half-dose depot triptorelin is the same as reduced-dose daily buserelin in a long protocol of controlled ovarian stimulation for ICSI/embryo transfer: A randomized double-blind clinical trial (NCT00461916). Hum Reprod. 2007;22:2449-54.
121. Salib RJ, Howarth PH. Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis. Drug Saf. 2003;26:863-93.
122. Sastre J, Mosges R. Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol. 2012;22:1-12.
123. Schulz C, Paulus K, Jöhren O, et al. Intranasal leptin reduces appetite and induces weight loss in rats with diet-induced obesity (DIO). Endocrinology. 2012;153: 143-53.
124. Seju U, Kumar A, Sawant KK. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: In vitro and in vivo studies. Acta Biomater. 2011;7:4169-76.
125. Shao Z, Park GB, Krishnamoorthy R, et al. The physicochemical properties, plasma enzymatic hydrolysis, and nasal absorption of acyclovir and its 2′-ester prodrugs. Pharm Res. 1994;11:237-42.
126. Sharma S, Mukkur TK, Benson HA, et al. Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. J Pharm Sci. 2009; 98:812-43.
127. Shore N, Cookson MS, Gittelman MC. Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer. BJU Int. 2012;109:226-32.
128. Simon JK, Ramirez K, Cuberos L, et al. Mucosal IgA responses in healthy adult volunteers following intranasal spray delivery of a live attenuated measles vaccine. Clin Vaccine Immunol. 2011; 18:355-61.
129. Singh AK, Singh A, Madhav NV. Nasal cavity: A promising transmucosal platform for drug delivery and research approaches from nasal to brain targeting. J Drug Deliv Ther. 2012;2:22-33.
130. Steyn D, du Plessis L, Kotzé A. Nasal delivery of recombinant human growth hormone: In vivo evaluation with Pheroid technology and N-trimethyl chitosan chloride. J Pharm Pharm Sci. 2010;13:263-73.
131. Stoker DG, Reber KR, Waltzman LS, et al. Analgesic efficacy and safety of morphine-chitosan nasal solution in patients with moderate to severe pain following orthopedic surgery. Pain Med. 2008;9:3-12.
132. Suh JD, Kennedy DW. Treatment options for chronic rhinosinusitis. Proc Am Thorac Soc. 2011;8:132-40.
133. Sur D, Scandale S. Treatment of allergic rhinitis. Am Fam Physician. 2010;81:1440-6.
134. Takeuchi S, Minoura H, Shibahara T, et al. A prospective randomized comparison of routine buserelin acetate and a decreasing dosage of nafarelin acetate with a low-dose gonadotropin-releasing hormone agonist protocol for in vitro fertilization and intracytoplasmic sperm injection. Fertil Steril. 2001;76:532-7.
135. Tas C, Ozkan CK, Savaser A, et al. Nasal administration of metoclopramide from different dosage forms: In vitro, ex vivo, and in vivo evaluation. Drug Deliv. 2009;16:167-75.
136. Teshima D, Yamauchi A, Makino K, et al. Nasal glucagon delivery using microcrystalline cellulose in healthy volunteers. Int J Pharm. 2002;233:61-6.
137. Thorne RG, Frey 2nd WH. Delivery of neurotrophic factors to the central nervous system: Pharmacokinetic considerations. Clin Pharmacokinet. 2001;40:907-46.
138. Thorne RG, Pronk GJ, Padmanabhan V, et al. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience. 2004;127:481-96.
139. Thorne RG, Hanson LR, Ross TM, et al. Delivery of interferon- beta to the monkey nervous system following intranasal administration. Neuroscience. 2008;152: 785-97.
140. Tiwari S, Verma SK, Agrawal GP, et al. Viral protein complexed liposomes for intranasal delivery of hepatitis B surface antigen. Int J Pharm. 2011;413:211-9.
141. Treschan TA, Peters J. The vasopressin system: Physiology and clinical strategies. Anesthesiology. 2006;105: 599-612.
142. Tribble D, Kaminski R, Cantrell J, et al. Safety and immunogenicity of a shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers. Vaccine. 2010;28:6076-85.
143. Tunn UW. A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: A non-interventional prospective study in 1273 patients. BMC Urol. 2011;11:15.
144. Tutykhina IL, Logunov DY, Shcherbinin DN, et al. Development of adenoviral vector-based mucosal vaccine against influenza. J Mol Med (Berl). 2011;89: 331-41.
145. Tuvemo T, Gustafsson J, Proos LA. Suppression of puberty in girls with short-acting intranasal versus subcutaneous depot GnRH agonist. Horm Res. 2002;57:27-31.
146. Tveita T, Thoner J, Klepstad P, et al. A controlled comparison between single doses of intravenous and intramuscular morphine with respect to analgesic effects and patient safety. Acta Anaesthesiol Scand. 2008; 52:920-5.
147. Uchida M, Katoh T, Mori M, et al. Intranasal administration of milnacipran in rats: evaluation of the transport of drugs to the systemic circulation and central nervous system and the pharmacological effect. Biol Pharm Bull. 2011;34:740-7.
148. Uemura N, Onishi T, Mitaniyama A, et al. Bioequivalence and rapid absorption of zolmitriptan nasal spray compared with oral tablets in healthy Japanese subjects. Clin Drug Investig. 2005;25:199-208.
149. Vaidyanathan S, Williamson P, Clearie K, et al. Fluticasone reverses oxymetazoline-induced tachyphylaxis of response and rebound congestion. Am J Respir Crit Care Med. 2010;182:19-24.
150. Van de Walle J, Stockner M, Raes A, et al. Desmopressin 30 years in clinical use: A safety review. Curr Drug Saf. 2007;2:232-8.
151. Van de Walle J, Van Herzeele C, Raes A. Is there still a role for desmopressin in children with primary monosymptomatic nocturnal enuresis?: A focus on safety issues. Drug Saf. 2010;33:261-71.
152. Ved PM, Kim K. Poly(ethylene oxide/propylene oxide) copolymer thermo-reversible gelling system for the enhancement of intranasal zidovudine delivery to the brain. Int J Pharm. 2011;411:1-9.
153. Velasquez LS, Shira S, Berta AN, et al. Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine. Vaccine. 2011;29: 5221-31.
154. Veronesi MC, Kubek DJ, Kubek MJ. Intranasal delivery of neuropeptides. Methods Mol Biol. 2011;789:303-12.
155. Vyas TK, Shahiwala A, Marathe S, et al. Intranasal drug delivery for brain targeting. Curr Drug Deliv. 2005a;2:165-75.
156. Vyas TK, Babbar AK, Sharma RK, et al. Intranasal mucoadhesive microemulsions of zolmitriptan: Preliminary studies on brain-targeting. J Drug Target. 2005b;13:317-24.
157. Vyas TK, Babbar AK, Sharma RK, et al. Intranasal mucoadhesive microemulsions of clonazepam: Preliminary studies on brain targeting. J Pharm Sci. 2006a; 95:570-80.
158. Vyas TK, Babbar AK, Sharma RK, et al. Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. AAPS PharmSciTech. 2006b;7:E8.
159. Wang SH, Kirwan SM, Abraham SN, et al. Stable dry powder formulation for nasal delivery of anthrax vaccine. J Pharm Sci. 2012;101:31-47.
160. Wei SQ, Luo ZC, Qi HP, et al. High-dose vs low-dose oxytocin for labor augmentation: A systematic review. Am J Obstet Gynecol. 2010;203:296-304.
161. Wells J. Mucosal vaccination and therapy with genetically modified lactic acid bacteria. Annu Rev Food Sci Technol. 2011;2:423-45.
162. Westin U, Piras E, Jansson B, et al. Transfer of morphine along the olfactory pathway to the central nervous system after nasal administration to rodents. Eur J Pharm Sci. 2005;24:565-73.
163. Westin UE, Boström E, Gråsjö J, et al. Direct nose-tobrain transfer of morphine after nasal administration to rats. Pharm Res. 2006;23:565-72.
164. Wilson JM. Gendicine: The first commercial gene therapy product. Hum Gene Ther. 2005;16:1014-5.
165. Wolfe TR, Bernstone T. Intranasal drug delivery: An alternative to intravenous administration in selected emergency cases. J Emerg Nurs. 2004;30:141-7.
166. Wu Y, Wei W, Zhou M, et al. Thermal-sensitive hydrogel as adjuvant-free vaccine delivery system for H5N1 intranasal immunization. Biomaterials. 2012; 33:2351-60.
167. Xu J, Dai W, Wang Z, et al. Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen a protects mice against nasopharyngeal colonization by Streptococcus pneumoniae. Clin Vaccine Immunol. 2011;18:75-81.
168. Yang T, Hussain A, Bai S, et al. Positively charged polyethylenimines enhance nasal absorption of the negatively charged drug, low molecular weight heparin. J Control Release. 2006;115:289-97.
169. Yates R, Sörensen J, Bergström M, et al. Distribution of intranasal 11 C-zolmitriptan assessed by positron emission tomography. Cephalalgia. 2005; 25:1103-9.
170. Youn YS, Jeon JE, Chae SY, et al. PEGylation improves the hypoglycaemic efficacy of intranasally administered glucagon-like peptide-1 in type 2 diabetic db/db mice. Diabetes Obes Metab. 2008;10:343-6.
171. Zaki NM, Mortada ND, Awad GA, et al. Rapid-onset intranasal delivery of metoclopramide hydrochloride Part II: Safety of various absorption enhancers and pharmacokinetic evaluation. Int J Pharm. 2006;327: 97-103.
172. Zaman M, Simerska P, Toth I. Synthetic polyacrylate polymers as particulate intranasal vaccine delivery systems for the induction of mucosal immune response. Curr Drug Deliv. 2010; 7:118124.
173. Zhang YJ, Ma CH, Lu WL, et al. Permeation-enhancing effects of chitosan formulations on recombinant hirudin- 2 by nasal delivery in vitro and in vivo. Acta Pharmacol Sin. 2005;26:1402-8.
174. Zhang J, Branch DW, Ramirez MM, et al. Oxytocin regimen for labor augmentation, labor progression, and perinatal outcomes. Obstet Gynecol. 2011; 118:249-56.